# Novo Nordisk A/S (NYSE: NVO), Bagsvard, Denmark – FDA Inspections

Source: https://www.keypedia.com/companies/novo-nordisk-as/99c36868-1f84-44c1-8e90-7abc30e92ec3

> Inspection records and compliance data for Novo Nordisk A/S in Bagsvard. 9 FDA inspections on record (1 OAI), 1 Form 483, last inspected March 29, 2023. Publicly traded as NYSE: NVO.

---

## Details

- Name: Novo Nordisk A/S
- FEI Number: 3000151819
- Address Line 1: Novo Alle 1
- City: Bagsvard
- Country Name: Denmark
- Address: Novo Alle 1, Bagsvard, Denmark
- Country: Denmark

## Stock

- Stock ticker: NVO
- Exchange: NYSE
- Share price: $40.66
- Market cap: $180.0B
- Price as of: November 13, 2026

## Related Documents

- FDA Inspection 1245306 - Novo Nordisk A/S - 2023-03-29 — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 29, 2023
- [FDA Inspection 1165895 - Novo Nordisk A/S - 2019-12-05](https://www.keypedia.com/records/fda_inspections/novo-nordisk-as/1b2e0386-bb32-4a1e-b8c0-6bda25e404ad) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 5, 2019
- FDA Inspection 1057438 - Novo Nordisk A/S - 2018-05-18 — classification: No Action Indicated (NAI), source: FDA, date: May 18, 2018
- FDA Inspection 1057438 - Novo Nordisk A/S - 2018-05-18 — classification: No Action Indicated (NAI), source: FDA, date: May 18, 2018
- [FDA Inspection 1007260 - Novo Nordisk A/S - 2017-02-08](https://www.keypedia.com/records/fda_inspections/novo-nordisk-as/f7c9c747-d7de-4a6c-9886-e185d08b2706) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 8, 2017
- FDA Inspection 964462 - Novo Nordisk A/S - 2016-04-08 — classification: No Action Indicated (NAI), source: FDA, date: April 8, 2016
- [FDA Inspection 846713 - Novo Nordisk A/S - 2013-09-03](https://www.keypedia.com/records/fda_inspections/novo-nordisk-as/d4ee5da4-3a33-41c2-bf98-f33b8e2cca57) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 3, 2013
- [FDA Inspection 779822 - Novo Nordisk A/S - 2012-03-20](https://www.keypedia.com/records/fda_inspections/novo-nordisk-as/0b479073-dd1d-404d-bc3a-9c85aa0dfabc) — classification: Official Action Indicated (OAI), source: FDA, date: March 20, 2012
- FDA Inspection 583274 - Novo Nordisk A/S - 2009-05-13 — classification: No Action Indicated (NAI), source: FDA, date: May 13, 2009
- FDA Inspection 584325 - Novo Nordisk A/S - 2009-03-06 — classification: No Action Indicated (NAI), source: FDA, date: March 6, 2009

## Related Companies

- [Honour Lab Limited](https://www.keypedia.com/companies/honour-lab-limited/527808a4-97a5-4c5b-8698-4dc2ab4bdeba)
- [Zhejiang Medicine Co. Ltd. Xinchang Pharmaceutical Factory](https://www.keypedia.com/companies/zhejiang-medicine-co-ltd-xinchang-pharmaceutical-factory/e800486e-60a0-49f5-8d0b-02f5ce3f408c)
- [Niagara Pharmaceuticals Inc](https://www.keypedia.com/companies/niagara-pharmaceuticals-inc/86d1fc76-da98-4df3-bf23-bed8075fdd53)
- [Zhejiang Charioteer Pharmaceutical Co. Ltd.](https://www.keypedia.com/companies/zhejiang-charioteer-pharmaceutical-co-ltd/1b311d6e-f732-4126-b220-37035ec0877b)
- [Recordati Industria Chimica E Farmaceutica S.p.A.](https://www.keypedia.com/companies/recordati-industria-chimica-e-farmaceutica-spa/64c85811-b0b7-49d3-92ba-be4ef940fe66)
- [Shandong Ruiying Pioneer Pharmaceutical Co., Ltd](https://www.keypedia.com/companies/shandong-ruiying-pioneer-pharmaceutical-co-ltd/574c4f09-5a4e-4428-b84d-cb139c05ff9b)
- [Curium US PET LLC](https://www.keypedia.com/companies/curium-us-pet-llc/0bdd3dc2-1a8a-46ec-819b-0a1d58ac2e15)
- [Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/zhejiang-apeloa-kangyu-pharmaceutical-co-ltd/3fca869b-8499-4731-95c4-d6a48fb2cdb0)
- [Wuxi Fortune Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/wuxi-fortune-pharmaceutical-co-ltd/d02f3e8d-af2b-4b82-b2ae-6fc25c005e95)
- [International Isotopes Inc.](https://www.keypedia.com/companies/international-isotopes-inc/45d80b73-be9e-40fb-978b-66683f25c070)